Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and POETYK PSO-LTE Trials

被引:0
|
作者
Lebwohl, Mark [1 ]
Warren, Richard B. [2 ]
Kircik, Leon [1 ]
Colston, Elizabeth [3 ]
Hippeli, Lauren [3 ]
Napoli, Andrew [3 ]
Kisa, Renata M. [3 ]
Banerjee, Subhashis [3 ]
Menter, Alan [4 ]
Thaci, Diamant [5 ]
Blauvelt, Andrew [6 ]
机构
[1] Icahn Sch Med Mt Sinai, New York, NY USA
[2] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, NIHR Manchester Biomed Res Ctr, Manchester, England
[3] Bristol Myers Squibb, New York, NY USA
[4] Baylor Univ, Med Ctr, Waco, TX USA
[5] Univ Lubeck, Lubeck, Germany
[6] Oregon Med Res Ctr, Portland, OR USA
关键词
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
43851
引用
收藏
页码:AB35 / AB35
页数:1
相关论文
共 50 条
  • [41] Deucravacitinib Treatment Did Not Impact Immune Response to SARS-CoV-2 Vaccines and Infection in Patients with Plaque Psoriasis: Results from the Phase 3 POETYK Long-Term Extension Trial
    Winthrop, Kevin
    Merola, Joseph
    Morita, Akimichi
    Thaci, Diamant
    Zhang, Jianzhong
    Ba, Aditi Basu
    Catlett, Ian M.
    Schwarz, John
    Luo, Yi
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4165 - 4167
  • [42] Cumulative clinical benefit over 52 weeks comparing initiation with deucravacitinib versus apremilast in patients with moderate to severe plaque psoriasis: a post hoc analysis of POETYK PSO-1 trial results stratified by prior treatment
    Armstrong, April W.
    Park, Sang Hee
    Patel, Vardhaman
    Nicolas, Pierre
    Wang, Wei-Jhih
    Colombo, Matthew J.
    Chirikov, Viktor
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB30 - AB30
  • [43] Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Scalp, Nail, and Palmoplantar Psoriasis in Japanese Patients With Plaque Psoriasis: Subset Analysis of the Phase 3 POETYK PSO-4 Trial
    Imafuku, Shinichi
    Okubo, Yukari
    Tada, Yayoi
    Ohtsuki, Mamitaro
    Shao, Yanqiu
    Colston, Elizabeth
    Kisa, Renata M.
    Banerjee, Subhashis
    Morita, Akimichi
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB147 - AB147
  • [44] Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe plaque psoriasis: Improvement in body surface area involvement in the phase 3 POETYK PSO-3 trial
    Zhang, J.
    Ding, Y.
    Wang, P.
    Li, L.
    Pan, W.
    Lu, Y.
    Liu, L.
    Kisa, R. M.
    Hoyt, K.
    Banerjee, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S109 - S109
  • [45] Certolizumab pegol for plaque psoriasis: 2-year efficacy results from 2 phase 3 trials (CIMPASI-1 and CIMPASI-2)
    Gordon, K.
    Reich, K.
    Blauvelt, A.
    Thaci, D.
    Leonardi, C.
    Poulin, Y.
    Boehnlein, M.
    Kavanagh, S.
    Arendt, C.
    Gottlieb, A. B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB179 - AB179
  • [46] Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)
    Gordon, K. B.
    Warren, R. B.
    Gottlieb, A. B.
    Blauvelt, A.
    Thaci, D.
    Leonardi, C.
    Poulin, Y.
    Boehnlein, M.
    Brock, F.
    Ecoffet, C.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (04) : 652 - 662
  • [47] Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 1
    Crowley, Jeffrey
    Korman, Neil J.
    Spelman, Lynda
    Igarashi, Atsuyuki
    Gupta, Aditya K.
    Mendelsohn, Alan M.
    Rozzo, Stephen J.
    Eads, Kimberly M.
    Guenthner, Scott T.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB162 - AB162
  • [48] Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 2
    Langley, Richard G.
    Gooderham, Melinda
    Papp, Kim Alexander
    Yamauchi, Paul
    Thaci, Diamant
    Parno, Jeff
    Mendelsohn, Alan M.
    Rozzo, Stephen J.
    Menter, Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB163 - AB163
  • [49] Tapinarof cream for the treatment of plaque psoriasis: Efficacy and safety results from 2 Japanese phase 3 trials
    Igarashi, Atsuyuki
    Tsuji, Gaku
    Fukasawa, Shuichi
    Murata, Ryusei
    Yamane, Satoshi
    JOURNAL OF DERMATOLOGY, 2024, 51 (10): : 1269 - 1278
  • [50] Efficacy of tildrakizumab in patients with chronic plaque psoriasis: Results from long-term extensions to 2 phase 3 clinical studies
    Papp, K.
    Reich, K.
    Blauvelt, A.
    Thaci, D.
    Kimball, A.
    Sinclair, R.
    Tyring, S.
    Cichanowitz, N.
    Green, S.
    Li, Q.
    La Rosa, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 108 - 108